Prednisone

證據等級: L5

預測適應症: 10 個

Prednisone: From Systemic Inflammatory Conditions to Alopecia Areata

One-Sentence Summary

Prednisone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects, classically used for a wide range of autoimmune, inflammatory, and allergic disorders. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 directly relevant completed Phase 3 RCT (NCT02037191) and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Systemic anti-inflammatory and immunosuppressive therapy (autoimmune, inflammatory, and allergic conditions)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Prednisone is a synthetic glucocorticoid that binds intracellular glucocorticoid receptors to trigger broad anti-inflammatory and immunosuppressive effects. Although detailed MOA data was not retrieved in this evidence pack, prednisone’s pharmacology is well established: it inhibits phospholipase A2 (PLA2) to reduce prostaglandin and leukotriene synthesis, suppresses NF-κB to downregulate IL-1β, TNF-α, IL-6, and IFN-γ, curtails IL-2 production to impair CD8⁺ T-cell proliferation, and stabilizes lysosomal membranes to limit collateral tissue damage.

Alopecia areata (AA) is a CD8⁺ T-cell–mediated autoimmune disorder in which autoreactive cytotoxic T cells breach the immune privilege of hair follicles, generating the characteristic perifollicular “swarm of bees” lymphocytic infiltrate. This mechanism maps directly onto prednisone’s strengths: suppression of the T-cell–driven cascade can theoretically restore the follicular immune sanctuary and permit hair regrowth. Clinical use of systemic corticosteroids in AA dates back to the 1950s, reflecting longstanding recognition of this mechanistic alignment.

Modern guidelines have shifted toward JAK inhibitors (baricitinib, ritlecitinib) for sustained remission in severe AA owing to more durable responses. However, prednisone remains clinically relevant as acute bridging therapy, as a combination partner with methotrexate — a role directly validated by a 2023 JAMA Dermatology RCT (PMID 36884234) — and for rapid suppression of rapidly progressing disease. The mechanistic basis is solid even if long-term monotherapy is no longer considered optimal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02037191	Phase 3	Completed	90	Randomized double-blind study evaluating methotrexate vs placebo in severe alopecia areata totalis/universalis, with a secondary treatment arm of methotrexate combined with low-dose prednisone; the most directly relevant trial for prednisone’s role in severe AA
NCT03843125	Phase 3	Terminated	1,147	Long-term safety and efficacy of baricitinib in AA; prednisone used as rescue or concomitant medication, providing contextual evidence for corticosteroid use in this indication; terminated early — efficacy data require cautious interpretation
NCT05162586	Phase 2	Completed	456	Dose-ranging study of enpatoran in SLE/CLE on standard of care; prednisone permitted as background therapy, situating its role within immune-mediated dermatologic disease management
NCT02437890	Phase 2	Completed	312	ALX-0061 (anti-IL-6R antibody) in moderate-to-severe SLE; steroid reduction was a prespecified secondary endpoint, highlighting prednisone as the immunosuppressive anchor against which newer biologics are benchmarked

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36884234	2023	RCT	JAMA Dermatology	2-step double-blind RCT (n=90): methotrexate + low-dose prednisone significantly improved complete hair regrowth rates in alopecia totalis/universalis vs methotrexate alone; strongest current RCT evidence for low-dose prednisone in severe AA
37467740	2023	Case Series	Clinical and Experimental Dermatology	8-case series: combination of baricitinib + low-dose corticosteroids achieved major improvement in very severe AA (SALT ≥95) where baricitinib monotherapy had failed; supports prednisone as a potentiating agent
26735937	2016	Cohort Study	Dermatology (Basel)	Methotrexate combined with low-to-moderate dose corticosteroids in severe AA; reports response rates and tolerability supporting the combination regimen
38650498	2024	Real-world Evidence	Italian Journal of Dermatology and Venereology	National real-world analysis of hospitalized AA patients in Italy; documents treatment patterns including corticosteroid use, comorbidities, and economic burden
1444509	1992	Review	Archives of Dermatology	Comprehensive review of AA therapy covering corticosteroids, DNCB, PUVA, and other modalities; discusses efficacy, safety, and mechanistic underpinnings of prednisone in various AA severity levels
791152	1976	Follow-up Study	Archives of Dermatology	18 patients on alternate-day prednisone for AA followed for mean 15 months post-treatment; initial hair regrowth response observed but long-term benefit limited; multiple side effects documented
4571041	1973	Interventional Study	Archives of Dermatology	Early immunologic characterization of AA with prednisone treatment; foundational documentation of the immunosuppressive approach in this condition
20804894	2010	Clinical Study	Annales de Dermatologie et de Vénéréologie	Evaluated monthly oral pulse prednisone for AA; assessed efficacy and safety of pulsed corticosteroid dosing as an alternative to continuous therapy
8996277	1997	Clinical Study	Journal of the American Academy of Dermatology	Systemic cyclosporine + low-dose prednisone in severe chronic AA; clinical and immunopathologic evaluation of the combination approach
23962142	2013	Case Report	Journal of Cutaneous Pathology	AA-like diffuse scalp alopecia with prominent follicular mucinosis achieved complete resolution with oral prednisone; illustrates prednisone’s efficacy across the AA-spectrum of immune-mediated alopecia

Philippines Market Information

Prednisone currently has no registered products with FDA Philippines (market status: Not Marketed, 0 active licenses). Should this repurposing candidate be advanced, a new drug registration application with FDA Philippines would be required before commercial availability.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic case is compelling — prednisone directly targets the CD8⁺ T-cell–driven immunopathology of alopecia areata — and this is reinforced by a completed Phase 3 RCT (NCT02037191) and a published 2023 JAMA Dermatology RCT (PMID 36884234) demonstrating superior hair regrowth when low-dose prednisone is combined with methotrexate in alopecia totalis/universalis. Evidence level L2 is met. However, the absence of a Philippines market registration, missing formal safety documentation, and the evolving treatment landscape (JAK inhibitors now preferred for severe AA) necessitate guardrails before advancing.

To proceed, the following is needed:

Regulatory pathway: Initiate FDA Philippines drug registration for prednisone (currently 0 active licenses)
Safety documentation: Obtain and review the full prescribing information — contraindications, black-box warnings, and drug interactions were not retrievable in this evidence pack
DDI assessment: Full drug-drug interaction profile not available; must be completed before clinical use
Target population definition: Specify intended AA severity stratum (mild patch vs severe/totalis/universalis) and clarify intended role (monotherapy induction, bridging to JAK inhibitor, or combination with methotrexate)
Dosing regimen: Confirm preferred schedule (daily low-dose, alternate-day, or monthly oral pulse) based on available evidence
Long-term safety monitoring plan: Address known corticosteroid risks — HPA axis suppression, metabolic syndrome, osteoporosis, ocular complications, and infection risk — with defined monitoring intervals
Positioning vs JAK inhibitors: Clarify how prednisone fits within current AA treatment algorithms given that baricitinib and ritlecitinib now hold formal regulatory approvals for severe AA
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.